Thera-SAbDab

URELUMAB

>   Structural Summary
TherapeuticUrelumab
TargetTNFRSF9
Heavy ChainQVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQSPEKGLEWIGEINHGGYVTYNPSLESRVTISVDTSKNQFSLKLSSVTAADTAVYYCARDYGPGNYDWYFDLWGRGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPALTFGGGTKVEIK
100% seqID Fv Structure6mhr [Fvs: AB, DE]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedBristol-Myers Squibb, National Cancer Institute (USA), Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University of Chicago, Medarex
Conditions Approvedna
Conditions ActiveNon-Hodgkin's lymphoma, Solid tumours, Glioblastoma, Multiple myeloma
Conditions DiscontinuedColorectal cancer, Head and neck cancer, Malignant melanoma, Non-small cell lung cancer
NotesJain paper: "VL sequence modified at one position to match patent document (US7659384) and JK germline"

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]